Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

Inclusion criteria: * Female (both pre- and postmenopausal) or male patients * Age ≥18 years * Ongoing adjuvant ET (tamoxifen or OFS plus tamoxifen or OFS plus AI or AI ) for ER positive HER2 negative breast cancer stages I-III * Patients must have received at least 3 months and up to 3 years of ET and planned to continue ET during the study conduction * Present endocrine therapy related MSK pain (arthralgia and/or bone pain and/or myalgias), evaluated by the treating clinician as at least grade 2 CTCAE V5.0 for, at least, 4 weeks before enrolment, at the time of the clinic visit: * Grade 2: moderate pain; limiting instrumental activities daily living (ADL) * Grade 3: severe pain; limiting activities self-care ADL * Previous chemotherapy is allowed if completed at least 3 months before enrolment * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 * Adequate organ function * Completed baseline assessment of patient-reported questionnaires (EORTC QLQ-C30 and EORTC QLQ breast module) * Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations * Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 7 days prior to the first dose of study treatment. Note: women of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e., females who have had any evidence of menses in the past 12 months, except for those who had …